UBS lowered the firm’s price target on Veracyte (VCYT) to $42 from $49 and keeps a Buy rating on the shares. UBS sees durable growth in Veracyte’s core products, as well as long-term growth potential from minimal residual disease testing, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VCYT: